40106-31-8

Basic information

• Product Name: 3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one
• Synonyms: 3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one;6,7,8,9-tetrahydro-3H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4(5H)-one;8-thia-4,6-diazatricyclo[7.5.0.0,]tetradeca-1(9),2(7),5-trien-3-one
• CAS NO: 40106-31-8
• Molecular Formula: C₁₁H₁₂N₂OS
• Molecular Weight: 220.29078
• Mol File: 40106-31-8.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 491.9°Cat760mmHg
• Flash Point: 251.3°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 8.06E-10mmHg at 25°C
• Refractive Index: 1.769
• CAS DataBase Reference: 3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one(40106-31-8)
• EPA Substance Registry System: 3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one(40106-31-8)

Safety Data

• Hazardous Substances Data: 40106-31-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H12N2OS/c14-10-9-7-4-2-1-3-5-8(7)15-11(9)13-6-12-10/h6H,1-5H2,(H,12,13,14)

Upstream product

• 64-18-6 formic acid 
• 23917-22-8 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbonitrile 
• 502-42-1 cycloheptanone 
• 77287-34-4 formamide 
• 40106-12-5 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 
• 350997-73-8 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
• 40106-13-6 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid ethyl ester 
• 3473-63-0 formamidine acetic acid 
• 40106-58-9 4-chloro-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3- d]pyrimidine 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 40106-58-9 4-chloro-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3- d]pyrimidine 
• 380907-31-3 1-(3,5-dimethyl-1H-pyrazol-1-yl)cyclohepta(b)thieno[2,3-d]pyrimidine 
• 40106-59-0 1-hydrazino cyclohepta(b)thieno[2,3-d]pyrimidine 
• 1345512-69-7 N'-[(3-hydroxyphenyl)methylene]-(4-oxo-6,7,8,9-tetrahydro-5H-cyclohepta [4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazone 
• 1345512-71-1 N'-[(4-hydroxyphenyl)methylene]-(4-oxo-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)acetohydrazone 
• 462084-68-0 C₁₇H₁₆N₂OS 
• 1395225-34-9 C₁₇H₁₅FN₂OS 
• 847786-13-4 N-cyclopropyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-amine 
• 924121-98-2 4-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 
• 379256-89-0 4-(4-phenylpiperazine-1-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine 

Relevant articles and documents

Cycloalkyl thienopyrimidinone compounds as well as preparation method and application thereof

The invention relates to a parent nucleus compound containing cycloalkyl[4,5]thieno[2,3-d]pyrimidin-4 (3H)-one, and the parent nucleus compound has the following structure shown in the specification,wherein R1, X, m and n are defined in the specification.

Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile

Aim: Design and synthesis of thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors.Material and methods: A series of novel 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine derivatives with different substituents on C-4 position was synthesized and evaluated for their anticancer activity against MCF-7 cell line. EGFR, VEGFR-2 inhibitory assay, the cell cycle analysis and apoptosis induction ability of the most potent compound 5f were evaluated.Results: Most of the compounds showed moderate to significant anticancer activity. Compound 5f exhibited the most potent anticancer activity being 1.73- and 4.64-folds more potent than erlotinib and doxorubicin, respectively. Compound 5f showed potent EGFR inhibitory activity being 1.18-folds more potent than reference standard erlotinib and it also showed good VEGFR-2 inhibitory activity at the micromolar level with IC50 value 1.23?μM. Compound 5f caused induction of cell cycle arrest at G2/M phase and accumulation of cells in pre-G1 phase. Compound 5f induced cellular apoptosis.

Identification of 4-methoxythieno[2,3-d]pyrimidines as FGFR1 inhibitors

Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds binding with the ATP-acceptor site was determined using molecular docking methods and the dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated.